The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Adult patients with mucosal leishmaniasis (ML) were enrolled in a randomized, double-blind, placebo-controlled, dose-escalating clinical trial and were randomly assigned to receive three injections of either the LEISH-F1+MPL-SE vaccine (consisting of 5, 10, or 20μg recombinant Leishmania polyprotein LEISH-F1 antigen+25μg MPL ® -SE adjuvant) (n=36) or saline placebo (n=12). The study injections...
Forty-four adult patients with cutaneous leishmaniasis (CL) were enrolled in a randomized, double-blind, controlled, dose-escalating clinical trial and were randomly assigned to receive three injections of either the LEISH-F1+MPL-SE vaccine (consisting of 5, 10, or 20μg recombinant Leishmania polyprotein LEISH-F1 antigen+25μg MPL ® -SE adjuvant) (n=27), adjuvant alone (n=8), or saline placebo...
Healthy Colombian adult volunteers with no history of leishmaniasis were evaluated for evidence of previous subclinical infection with Leishmania based on the Montenegro skin test (MST). Twelve MST-positive subjects were enrolled in an open-label, uncontrolled clinical trial (the “MST-positive trial”) and received three injections of the LEISH-F1+MPL-SE vaccine (consisting of 10μg recombinant Leishmania...
We present here the identification and characterization of Leishmania sterol 24-c-methyltransferase (SMT), as well as data on protection of mice immunized with this Ag formulated in MPL ® -SE. Serological evaluation revealed that SMT is recognized by VL patients. C57BL/6 mice immunized with this vaccine candidate plus MPL ® -SE showed Ag-specific Th1 immune responses characterized...
Mouse mammary tumor viruses (MMTVs) encode superantigens that associate with major histocompatibility complex class II products on antigen-presenting cells and stimulate T cells in a Vβ-specific manner. This T cell activation is critical for completion of the viral life cycle and vertical transmission to the next generation. To investigate the functional significance of extensive viral superantigen...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.